BR3005-1

DRUG2 trials

Sponsors

Boryung Pharmaceutical Co., Ltd

Conditions

Type 2 Diabetes MellitusType2 Diabetes Mellitus

Phase 1

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 Under Fasting Conditions in Healthy Adult Volunteers

CompletedNCT06289920

Boryung Pharmaceutical Co., LtdType 2 Diabetes Mellitus

Start: 2024-03-02End: 2024-03-28Updated: 2024-05-24

A Study to Compare the Pharmacokinetics and the Safety Between a Fixed-dose Combination Administration of BR3005 and Co-administration of BR3005-1 and BR3005-2 Under Fed Conditions in Healthy Adult Volunteers

CompletedNCT06289933

Boryung Pharmaceutical Co., LtdType2 Diabetes Mellitus

Start: 2024-03-05End: 2024-04-03Updated: 2024-05-24